12 Engineered biocircuits that interface with living systems as plug-and-play constructs may enable 13 new applications for programmable therapies and diagnostics. We create biological bits (bbits) 14 using proteases -a family of pleiotropic, promiscuous enzymes -to construct the biological 
Introduction
including genetic circuits that sense-and-respond to dysregulated inflammation 8 or blood glucose 8 levels 9 . To date, the design of these biocircuits is principally focused on constructs that are 9 implemented in cell-based platforms -which require genome or protein engineering 10-13 -and 10 carry out algorithms inspired by classical computer circuits, which operate on binary digits (bits) 11 and Boolean logic gates (e.g., AND, OR, NAND).
12
While classical biocircuits are well-suited at performing deterministic tasks (e.g., input 13 determines output) 14 , the ability to perform inference-based tasks -such as identification of which 14 single input cause resulted in the observed output effect given multiple plausible inputs -are more 15 challenging. In contrast to classical circuits, probabilistic circuits, which operate on analog bits 16 characterized by a probability distribution of states, efficiently solve inference problems by 17 assigning a likelihood probability that each plausible input would produce the observed output 15 . 18 Probabilistic bits have been implemented with magnets (p-bits) [16] [17] [18] as well as photons and 19 electrons in quantum systems (qubits) 19, 20 . In medicine, differential diagnoses are fundamentally capable of executing both classical and probabilistic algorithms for therapeutic and diagnostic 1 applications.
2
In living organisms, high-level functions arise from intricate networks of enzymatic 3 activity that ultimately control complex systems ranging from immunity to blood homeostasis 24 . Among enzymes, proteases are both ubiquitous, comprising 2% of the human genome 25 , and 5 promiscuous, having the ability to cleave diverse substrate sequences (6-8 AA) in addition to their 6 putative target [26] [27] [28] [29] [30] [31] [32] [33] . To leverage these features for programmable medicine, we define protease 7 activity acting on a target substrate as a biological bit (bbit). Under a classical framework, a register 8 of bbits comprise distinct protease-substrate pairs that take on the binary state 1 above an activity 9 threshold ( Fig. 1A left., Fig. S1A ). By contrast, probabilistic bbits are constructed using 10 promiscuous proteases that act on two substrates simultaneously to create a state of superposition 11 where the probability of being measured in state 0 or 1 is based on relative substrate cleavage 12 velocities (v0 and v1) ( Fig. 1A right, Fig. S1B ). Here we use classical bbits to design a plug-and-
13
play therapeutic biocircuit capable of quantifying input bacterial activity and outputting a digital 14 drug dose to clear infected human blood (Fig 1B) . Under a probabilistic framework, we construct 15 diagnostic biocircuits using probability-based gates to first solve the oracle problem Learning
16
Parity with Noise (LPN), and then extend this system in vivo by treating networks of dysregulated 17 proteases as a hidden oracle to noninvasively diagnose pulmonary embolism with high accuracy 18 in a mouse model of thrombosis (Fig 1C) . 
Results

11
A central function of complex circuits is the ability to store and manipulate digitized information; 12 therefore, we first set out to construct a flash analog-to-digital converter (ADC) to convert 13 continuous biological signals into binary digits. An electronic ADC performs three major 14 operations during signal conversion: voltage comparison, priority assignment, and digital 15 encoding. An analog input voltage is first compared against a set of increasing reference voltages 16 (V0-Vi) by individual comparators (d0-di) that allows current to pass if the input signal is greater 17 than or equal to its reference value (Fig. S2) . During priority assignment, only the activated 18 comparator with the highest reference voltage, dn, remains on while all other activated 19 comparators, dn-1-d0 are turned off. The prioritized signal is then fed into a digital encoder 1 comprising OR gates to produce binary values. To design an ADC biocircuit using protease 2 activity as the core signal, we constructed biological analogs of comparators by using liposomes 3 locked by an outer peptide cage 34, 35 ( Fig. 2A; Fig. S3A, B) . With increasing peptide crosslinking 4 densities, these biocomparators (b0-bi) served to reference the level of input protease activity 5 (GzmB) required to fully degrade the peptide cage (IEFDSGK , Table S1 ) and expose the lipid 6 core ( Fig. S3C) substrates (RTKR and ENLYFQG) specific for the signal proteases (WNV and TEV respectively; biological ADC converted input protease levels (GzmB) across four orders of magnitude into 15 binary digital outputs (Fig. 2E, F) . measuring GzmB, WNV & TEV protease activity against respective substrates alone and in the presence of WNV 7 protease inhibitor. (E) Concentrations of GzmB across four orders of magnitude are input to the bioADC, and bbits 1 p0 and p1 are read out in a fluorescent assay (n = 3, paired two-way t-test). (F) Digital output as a function of input 2 GzmB concentration. * < 0.05, ** < 0.01, *** < 0.001, and **** < 0. 0001. 3 To demonstrate a practical biomedical application, we next sought to interface our 4 biological ADC with a living system as a plug-and-play therapeutic biocircuit for digital drug 5 delivery. We rewired our ADC to autonomously quantify input bacterial activity and then output 6 an anti-microbial drug dose to selectively clear infected red blood cells (RBCs) of bacteria (DH5α 7 Escherichia coli) (Fig. 3A) . To construct biocomparators with the ability to prioritize input levels 8 of bacterial activity, we synthesized liposomes with peptide cages using a substrate (RRSRRVK) 9 specific for the E. Coli surface protease OmpT 37,38 (Fig. 3B) . We synthesized a series of 8 10 biocomparators with increasing peptide densities (0-10.2 nM) and validated their ability to sense 11 input bacterial concentrations across 8 log units (0-10 8 CFU/ml) using a fluorescent reporter (Fig. 12 S6). To convert the release of signal proteases to a drug output, we designed protease-activatable 13 prodrugs comprising cationic (polyarginine) anti-microbial peptides (AMP) (Fig. 3C , Table S1 ) 14 in charge complexation with anionic peptide locks (polyglutamic acid) 39 to block the activity of 15 AMP. These drug-lock peptides were linked in tandem by OR gate peptides p0 and p1 (RTKR and 16 ENLYFQG respectively) to allow signal proteases that directly cleave p0 or p1 to digitally control 17 the output drug dose (Fig. 2) . We designed one-third and two-thirds of the total drug dose to be 18 unlocked by cleavage of p0 and p1, respectively, such that binary values 00, 01, 10, and 11 19 corresponded to 0/3, 1/3, 2/3, and 3/3 of the total drug dose (Fig. S7) .
20
To confirm the therapeutic efficacy of our prodrug design, treatment of bacteria with 21 locked drug had no significant cytolytic activity compared to untreated controls, but by contrast, 22 treatment with protease-cleaved drug-lock complexes resulted in a significant reduction in 23 bacterial colonies (Fig. 3D) . We observed similar levels of bacterial cytotoxicity when AMP was 24 directly loaded into liposomes, showing that charge complexation was required to fully block AMP 1 activity (Fig. S6B) . In human RBCs infected with E. coli at concentrations ranging from 10 0 -10 9 2 CFU/mL, samples containing a single biocomparator (b0) lacked the ability to eliminate bacteria 3 as anticipated (output = 00). By contrast, increasing the number of biocomparators in the samples 4 (b0-b3) allowed our program to autonomously increase the drug dose (output 01, 10, and 11) in 5 response to higher bacterial loads to completely eliminate infection burdens across 9 orders of 6 magnitude up to 10 9 CFU/mL without significantly increasing hemolysis (Fig. 3E, Fig. S8 ). Our 7 data showed that cell-free biocircuits can be constructed using protease activity as a primary digital 8 signal to execute autonomous drug delivery programs under a broad range of conditions. different number of biocomparators (two-way ANOVA & Sidak's multiple comparisons; hemolysis n = 2, cytotoxicity 7 n = 3). Line shading and error bars are standard deviation. * < 0.05, ** < 0.01, *** < 0.001, and **** < 0.0001. 8
Our antimicrobial ADC used protease activity as binary classical bbits to carry out a sense- state 0 or 1 with equal probability (i.e., performed by adding a second substrate to allow multi-6 target cleavage) (Fig. 4A, B) . By contrast, analogous to a classical XOR gate, we designed the L-7 gate to take two input bbits -control and target bbits b0 and b1 respectively -and operate on the 8 state 1 probability of target b1 such that it exhibits parity, or is linked, to the state 1 probability of 9 control b0 (i.e., performed by adding a second substrate to allow common-target cleavage between 10 two proteases) (Fig. 4C, Fig S9E) . We constructed biological scores, based on probabilistic 11 scores 42 , to implement all four instances of the 2-bit LPN problem by using our U-and L-gates to 12 operate on three protease bits -2 string bits (b0 and b1) to represent possible hidden string values 13 (00, 01, 10, and 11) and 1 answer bit (b2) (Fig. S9B , C, Table S1 , 2). By multiplying all 14 permutations of the output state 0 and 1 probabilities of bbits b0-b2 (Fig. S9D) , our protease solver 15 correctly deduced the value of the hidden string among all other possibilities by assigning it the 16 highest probability in all four oracle configurations ( Fig. 4E; Fig. S9D ). Collectively, our results
17
showed that protease activity can be quantified as state probabilities and operated by probabilistic 18 logic gates to efficiently solve inference problems. We next sought to demonstrate a practical application using probabilistic bbits as a 1 diagnostic platform for disease detection in living animals. The ability to detect dysregulated 2 protease activity has important diagnostic applications for broad diseases, such as the prothrombin 3 time (PTT) assay which is used to diagnose thrombosis 43 . Here we considered dysregulated 4 protease networks, such as those in thrombosis, to be represented as an oracle string of protease 5 activities with a distinct probability distribution compared to a healthy state (Fig. 5A) . Analogous 6 to the Central Limit Theorem (CLT), we postulated that designing promiscuous, common-target 7 substrates to detect dysregulated protease networks could be modeled as sampling a probability 8 distribution where sampling means would converge to normal distributions even if the underlying 9 protease probability distribution is itself not normally distributed. We therefore sought to design 10 and adapt a new set of U-gates to sample differences in uniformity between dysregulated and 11 healthy protease networks, and use the resulting normalized variances (σ 2 ) to discriminate disease 12 ( Fig 5A) .
13
To test this approach computationally, we randomly generated baseline activity scores greater than 90% classification accuracy can be achieved with >10 U-gates and >20 dysregulated 23 proteases) (Fig 5B) . Factor D, Factor I) and coagulation protease networks (e.g., thrombin, plasmin, factor XIIa, factor 4 Xa, protein C) (Fig S10) . Using the measured U-gate outputs after incubation with either group of 5 proteases in vitro (Fig 5C) , the normalized variances of the U-gate outputs classified mixtures as 6 either complement or coagulation with perfect accuracy (n = 10, AUROC = 1.00, Fig 5D) . These 7 results confirmed that a set of promiscuous U-gates can be used to sample and discriminate 8 differences in the underlying probability distributions of protease networks.
9
To apply this approach for in vivo diagnostics, we used a thromboplastin-induced mouse administered a single cocktail of our seven mass-barcoded U-gates to quantify protease activity in 17 healthy mice ( Fig. 5E; Fig. S11 ) 28 as well as in mice induced with PE ( Fig. 5F ). The measured strings of protease activity as a probability distribution, the underlying sample variance can be 1 used to infer and diagnose pulmonary embolism with high accuracy. involved were: Factor XIa (6 mg/mL), Plasmin (6.9 mg/mL), Thrombin (10.1 mg/mL), 32 and C1r (1 mg/mL). State 0 and State 1 peptide substrates were CC1 and CC6 for FXIa,
33
CC4 and CC1 for C1r, CC2 and CC6 for Thrombin, and CC2 and CC9 for Plasmin.
34
Probability of two digit state is calculated by multiplying the probability (relative sample was centrifuged at 1000 RPM for 10 min, and the supernatant was discarded. Increase 10-300 GL column using AKTA Pure FPLC System (GE Health Care Statistical analysis was performed using statistical packages included in GraphPad Prism 6.
8
To assess the significance of increase in signal due to protease cleavage, we used a two-way 9 ANOVA (without repeated measures) followed by Sidak's multiple comparisons test (Fig.   10 2B, C, and 3B). To assess the accuracy of assigning the binary value 0 or 1 to the digits p0 11 and p1 as seen in Fig. 2E , two-way paired t-tests were performed between the signal value 12 from each digit to determine if the signal from one was statistical more prominent than the 13 other (Fig. 2E, 4B, C) . A one-way ANOVA followed by Dunnett's multiple comparisons test 14 was used to compare experimental means to cells only control in Fig. 3D . Two-way ANOVA 15 followed by Sidak's multiple comparisons test used to compare experimental means to 16 control for bacterial cytotoxicity and RBC hemolysis (Fig. 3E) . 7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32 13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33 hiding a string of bits, which should be learned with the smallest number of oracle queries. Upon 5 each query, the oracle (1) generates a random string of bits and (2) takes the dot product of the 6 hidden and random strings, which produces the answer bit. Due to the definition of the dot 7 product, each time the answer bit takes on a value of 1, the oracle reveals which digits in the 8 hidden string may also take the value 1 (i.e., which digits in the hidden string exhibit parity with 9 the answer bit), eventually yielding the one correct string. However, in the presence of noise, or 10 uncertainty, the oracle makes mistakes that result in misinformation, making it more difficult to 11 infer the value of the hidden string. A quantum algorithm accounts for this uncertainty by 5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45 6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37 6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35 
